Actimmune Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to lack of alternative therapies for cgd, proven efficacy of interferon gamma therapy, orphan drug support policies, specialist immunology adoption, improved survival outcomes.

The growth in the forecast period can be attributed to rising diagnosis of rare immune disorders, increased access to specialty immunology centers, long term therapy adherence focus, supportive reimbursement frameworks, continued orphan drug investment. Major trends in the forecast period include growing use in rare immunodeficiency disorders, increased focus on immune modulation therapies, expansion of long term immune support treatments, improved management of chronic granulomatous disease, rising adoption in specialized immunology care.

The increasing incidence of infectious diseases is expected to drive the growth of the actimmune market in the coming years. Infectious diseases are conditions caused by harmful microorganisms such as bacteria, viruses, fungi, or parasites that enter the body, often spreading through direct contact, contaminated surfaces, or vectors, and their severity varies depending on the pathogen and the host’s immune response. The rise in infectious diseases is driven by factors including population growth, inadequate sanitation, climate change, and the emergence of new pathogens. Actimmune plays a role in combating infectious diseases by strengthening the immune system’s ability to detect and eliminate pathogens, including certain bacteria and viruses. It enhances immune responses by activating macrophages and other immune cells, thereby helping manage infections and reduce the severity of complications associated with immune deficiencies or chronic infections. For instance, in February 2024, according to the UK Health Security Agency, a UK-based government department, tuberculosis cases in England increased by 10.7% in 2023, rising from 4,380 in 2022 to 4,850. Therefore, the growing incidence of infectious diseases is contributing to the expansion of the actimmune market.

The increasing prevalence of chronic diseases is expected to support the growth of the actimmune market going forward. Chronic diseases are long-term conditions that last for a year or more and require continuous medical care or limit everyday activities. The rising burden of chronic diseases is driven by factors such as an aging population, unhealthy lifestyle habits, environmental factors, genetic predisposition, and improved diagnostic practices. Actimmune supports the management of chronic diseases by modulating immune responses and reducing inflammation, making it effective in treating conditions such as chronic granulomatous disease and severe malignant osteopetrosis, where it enhances immune function and slows disease progression. For instance, in April 2024, according to Allergy UK, a UK-based national charity, more than 21 million people in the UK were affected by allergies, which became the most commonly reported chronic health condition in 2022, and projections suggest that by 2026, half of Europe’s population will experience at least one allergy. Therefore, the rising prevalence of chronic diseases is driving the growth of the actimmune market.

In October 2023, Amgen Inc., a US-based biopharmaceutical company, acquired Horizon Therapeutics plc in a $27.8 billion deal. Through this acquisition, Amgen Inc. seeks to broaden its portfolio in oncology and cardiovascular therapies while strengthening its biotechnology and drug development capabilities to support future growth. Horizon Therapeutics plc is an Ireland-based biopharmaceutical company that focuses on actimmune, a therapy used to treat rare diseases such as chronic granulomatous disease and osteopetrosis.

Major companies operating in the actimmune market are Amgen Inc.

North America was the largest region in the actimmune market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the actimmune market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the actimmune market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have moderately impacted the actimmune market by increasing costs related to recombinant cytokine production and cold chain distribution. These impacts are most visible in hospital and specialty pharmacy procurement across north america and europe. Higher tariffs have placed pressure on rare disease therapy pricing. At the same time, tariffs are encouraging domestic biologic manufacturing initiatives. This supports long term treatment accessibility for immunodeficiency patients.

The actimmune market research report is one of a series of new reports that provides actimmune market statistics, including actimmune industry global market size, regional shares, competitors with a actimmune market share, detailed actimmune market segments, market trends and opportunities, and any further data you may need to thrive in the actimmune industry. This actimmune market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Actimmune is the brand name for interferon gamma-1b, a synthetic form of a naturally occurring protein that plays a key role in regulating the immune system. It is used in the treatment of chronic granulomatous disease (CGD) and severe malignant osteopetrosis by enhancing immune function to help fight infections and improve bone strength.

The main indications for Actimmune include chronic granulomatous disease (CGD), severe malignant osteopetrosis, and other related conditions. Chronic granulomatous disease is a rare inherited immunodeficiency disorder in which certain white blood cells are unable to effectively kill specific bacteria and fungi, resulting in recurrent infections and granuloma formation. It is used across pediatric and adult patient groups, among others, and is distributed through hospital pharmacies, specialty pharmacies, and online pharmacies to ensure wide access to the medication.

The actimmune market consists of sales of products such as subcutaneous injections and single-use vials. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.